ERBB2 and breast carcinoma: HER2CLIMB-02 (NCT03975647): This phase 3 trial, initiated in 2019, aimed to evaluate whether the combination of T-DM1 and tucatinib is more effective than T-DM1 alone in patients with advanced or metastatic HER2-positive breast cancer.